[Autoantibody profile in myositis].

Area of Science:

• Neurology
• Immunology
• Pathology

Context:

• Myopathies present with muscular symptoms or elevated creatine kinase, necessitating differentiation between acquired and genetic origins.
• Acquired myopathies require distinguishing between idiopathic types, specifically myositis (polymyositis, dermatomyositis, inclusion body myositis) and immune-mediated necrotizing myopathy, after excluding infectious, toxic, or endocrine factors.

Purpose:

• To highlight the critical role of autoantibody detection as a complementary tool to histopathology in diagnosing and classifying myopathies.
• To underscore the clinical significance of myositis-specific antibodies in predicting disease associations, clinical features, and patient survival.

Summary:

• Histopathology of muscle biopsy is essential, but autoantibody detection is increasingly crucial for myopathy diagnosis.
• Myositis-specific antibodies (e.g., anti-synthetase, anti-MDA-5, anti-TIF1-γ, anti-MI2) correlate with specific clinical syndromes and prognoses in dermatomyositis and polymyositis.
• Anti-SRP and anti-HMGCR antibodies aid in distinguishing acquired immune-mediated necrotizing myopathies from genetic muscular dystrophies, facilitating timely and effective therapeutic interventions.

Impact:

• This serologic approach refines myopathy classification, improving diagnostic accuracy and enabling personalized treatment strategies.
• Identifying specific autoantibodies allows for better prediction of disease course, associated complications (like interstitial lung disease or cancer), and patient outcomes.
• The integration of autoantibody testing into clinical practice supports the early initiation of appropriate therapies for immune-mediated myopathies, potentially improving patient prognosis.